GammaDelta’s Scientific Co-Founder Adrian Hayday Receives Inaugural Business of Science Leadership Award

About GammaDelta Therapeutics

GammaDelta Therapeutics has been founded on pioneering research into gamma delta (γδ) T cells led by Professor Adrian Hayday and Dr Oliver Nussbaumer at King’s College London and the Francis Crick Institute and funded in part by Cancer Research UK. The Company has a team of experienced management, strong academic pedigree and excellent potential for clinical development.

Founded in 2016, GammaDelta Therapeutics Ltd, is a breakthrough Immunotherapy company incubated by Abingworth. The company is supported by Cancer Research Technology, King’s College London and the Francis Crick Institute.

GammaDelta Therapeutics has been founded on pioneering research into gamma delta (γδ) T cells led by Professor Adrian Hayday and Dr Oliver Nussbaumer at King’s College London and the Francis Crick Institute, funded in part by Cancer Research UK. 

Gamma delta T cells are a unique and conserved population of lymphocytes that contribute to many types of immune responses and immunopathologies. The new company is focused on exploiting this work to develop improved immunotherapies for cancer and other serious immune related diseases.

A different class

GammaDelta Therapeutics’ technology is differentiated from other approaches to Immunotherapy and has the potential to make a significant impact on the treatment of cancer and other immune related diseases. The Company has a team of experienced management, strong academic pedigree and excellent potential for clinical development.